arrow
S

Sydney Ch'ng

Chris O'Brien Lifehouse
H指数:33
被引数:4,546

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial

黑色素瘤的新辅助治疗ipilimumab联合nivolumab: 来自2期PRADO试验的5年生存率和生物标志物分析

2026-01-280
PRE
Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma.

在临床上可检测的III期黑色素瘤中,新辅助免疫治疗后,通过减少肿瘤床检查,病理反应计算评估仍然准确。

2025-11-010
PRE
Predictive performance of the clinicopathologic gene expression profile (CP-GEP) in identifying cutaneous melanoma patients for whom sentinel lymph node biopsy is unnecessary: A systematic review and meta-analysis

临床病理基因表达谱(CP-GEP)在识别无需行前哨淋巴结活检的皮肤黑色素瘤患者中的预测性能:一项系统评价和荟萃分析

2025-06-200
PREAI
Nodal radioactivity after lymphoscintigraphy as a guide to sentinel node–positivity in melanoma patients

淋巴闪烁显像后的结节放射性作为黑色素瘤患者哨兵淋巴结阳性的指导

2025-06-090
OA
Global Applicability of a Risk Prediction Tool for Sentinel Node Positivity in Patients With Primary Cutaneous Melanoma

原发性皮肤黑色素瘤患者哨兵淋巴结阳性风险预测工具的全球适用性

2025-06-010
PRE
Cartilage Resection in the Surgical Management of Ear Melanoma

耳黑色素瘤手术管理中的软骨切除术

2025-04-280
OA
Comparison of clinicopathological features and treatment outcomes for cutaneous melanomas of the head and neck and melanomas arising at other sites: Implications for systemic therapy

头颈部皮肤黑色素瘤和其他部位黑色素瘤的临床病理特征和治疗结果的比较: 全身治疗的意义

2025-01-011
OAAI
Concurrent BRAF targeted therapy (TT) with dabrafenib and trametinib and anti-PD-1 agent pembrolizumab (PD1) increased B cell signalling and inflammatory pathways more effectively than when given sequentially or with anti-PD-1 alone

与序贯给药或仅使用抗PD-1药物相比,同时使用达拉非尼和曲美替尼的BRAF靶向治疗(TT)以及抗PD-1药物帕博利珠单抗(PD1)更能有效增强B细胞信号通路和炎症通路。

2024-09-010
PRE
Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas

前哨淋巴结阳性在线风险计算器对T1和T2黑色素瘤患者管理的影响

2024-07-030
PRE
Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial

帕博利珠单抗、达拉非尼和曲美替尼治疗BRAFV600-mutant可切除黑色素瘤的新辅助治疗: 随机2期NeoTrio试验

2024-06-213
OAAI
The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort

新辅助系统治疗对III期黑色素瘤淋巴结清扫术后手术结果的影响; 澳大利亚队列

2024-05-181
OAAI